Eltrombopag, also known by its CAS number 496775-61-2, is a medication used to treat low platelet counts in patients with chronic immune thrombocytopenia (ITP) and hepatitis C virus (HCV)-related thrombocytopenia. This product has gained attention in recent years due to its potential therapeutic benefits in treating these medical conditions.
Introduce this product: Eltrombopag is a medication that belongs to the class of drugs known as thrombopoietin receptor agonists. It works by stimulating the production of platelets in the bone marrow, helping to increase their numbers in the bloodstream. This helps to prevent bleeding and improve clotting ability in patients with low platelet counts.
Chemical name: The chemical name of Eltrombopag is (1S)-3'-[(2Z)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene]hydrazino]-[1,1'-biphenyl]-3-carboxylic acid.
Molecular formula: The molecular formula of Eltrombopag is C25H22N4O4.
Formula weight: The formula weight of Eltrombopag is 442.47 g/mol.
CAS No: The CAS number of Eltrombopag is 496775-61-2.
Top ten keywords from Google and Synonyms:
Synonyms for Eltrombopag include Promacta, Revolade, SB497115, and 496775-61-2.
Health benefits of this product: Eltrombopag has the potential to provide numerous health benefits in the treatment of various medical conditions. As a thrombopoietin receptor agonist, it can help increase platelet counts in patients with chronic immune thrombocytopenia and HCV-related thrombocytopenia. This can help prevent bleeding and improve clotting ability, reducing the risk of serious complications.
Potential effects: The potential effects of Eltrombopag are vast and varied. By stimulating the production of platelets in the bone marrow, it can help prevent bleeding and improve clotting ability in patients with low platelet counts. Additionally, Eltrombopag has shown promise in treating other medical conditions such as aplastic anemia, myelodysplastic syndrome, and chemotherapy-induced thrombocytopenia.
Product mechanism: Eltrombopag works by binding to and activating the thrombopoietin receptor, which stimulates the production of platelets in the bone marrow. This helps to increase the numbers of platelets in the bloodstream, improving clotting ability and preventing bleeding.
Safety: Eltrombopag has been extensively studied and has been found to be safe and effective in treating low platelet counts in patients with chronic immune thrombocytopenia and HCV-related thrombocytopenia. However, as with any medication, there is always some risk of side effects, and it is essential to consult a healthcare professional before starting any new medication or treatment regimen.
Side effects: Some potential side effects of Eltrombopag may include nausea, vomiting, headache, muscle pain, and dizziness. Additionally, there is a potential risk of liver toxicity, so regular monitoring of liver function tests is necessary during treatment.
Dosing information: The dosing of Eltrombopag will vary depending on the individual patient's medical condition, age, weight, and other factors. It is essential to follow the recommended dosing instructions provided by a healthcare professional, as taking too much or too little can affect its effectiveness and safety.
Conclusion: In conclusion, Eltrombopag shows significant potential in treating low platelet counts in patients with chronic immune thrombocytopenia and HCV-related thrombocytopenia. As a thrombopoietin receptor agonist, it provides greater efficacy and fewer side effects than non-selective treatments. However, more research is needed to confirm its efficacy and safety in treating other medical conditions. It is essential to consult a healthcare professional before starting any new medication or treatment regimen.
